Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluate Immuno and Safety of GSKBiologicals' HibMenCYTT vs Licensed Hib Conjugate Vaccine, Each Coadministered With Pediarix and Prevnar, in Healthy Infants. An Exploratory Control Group Will Receive Licensed Menomune at 3 to 5 Years.

X
Trial Profile

Evaluate Immuno and Safety of GSKBiologicals' HibMenCYTT vs Licensed Hib Conjugate Vaccine, Each Coadministered With Pediarix and Prevnar, in Healthy Infants. An Exploratory Control Group Will Receive Licensed Menomune at 3 to 5 Years.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hib-meningococcal vaccine groups C and Y conjugate (Primary) ; DTaP-hepatitis B-poliovirus vaccine; Hib vaccine conjugate; Meningococcal vaccine groups A C Y W-135 polysaccharide; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections; Pertussis; Pneumococcal infections; Poliomyelitis; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 23 Jul 2012 Status changed from active, no longer recruiting to completed.
    • 01 Jan 2010 Results published in the Pediatric Infectious Disease Journal.
    • 19 Nov 2007 Status change from in progress to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top